Retrospective Analysis of the Correlation of MSI-H/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

• DOI: 10.20944/preprints202306.0937.v1
• Publication Date: 2023-06-14T00:49:57Z
• Authors: Valentina Tuninetti; Luca Pace; Eleonora Ghisoni; Virginia Quarà; Francesca Arezzo; Andrea Palicelli; Vincenzo Dario Ma...; Elena Geuna; Gennaro Cormio; Nicoletta Biglia; Lucia Borsotti; Silvia Gallo; Annamaria Ferrero; Elena Jacomuzzi; Luca Fuso; Jeremy Oscar Smit...; Andrea Puppo; Andrea Caglio; Chiara Rognone; Margherita Turinetto; Giulia Scotto; Massimo Di Maio; Giorgio Valabrega
• Keywords: Microsatellite Instability

Background: There is poor evidence about sensitivity to chemotherapy according microsatellite instability (MSI)/mismatch repair (MMR) status in endometrial cancer (EC). 
 Methodology: The RAME study a retrospective analysis aiming assess response MSI-high (h) /deficient (d) MMR and MSI- low (l)/proficient (p)MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease progression-free (PFS) overall (OS) advanced/recurrent disease.
 Results: 312 treated between 2010-2022 4 high volume Multicenter Italian Trial Ovarian gynecological malignancies (MITO) centers selected. 239 had endometrioid (76.6%), 151 FIGO stage I at diagnosis (48.9%) 71 MSI-h/dMMR (22.8%). Median age was 65 (range 31–91) years. Among disease, median RFS 100.0 months (95%CI 59.4–140.7) MSI-l/pMMR 120.9 (60.0-181.8) (p=0.39). Seventy-seven received first-line disease. Patients ECs significantly worse OS (p=0.039). In receiving platinum-based chemotherapy, no statistically significant difference PFS (p=0.21) (p=0.057) detected, although numerically longer the population.
 Conclusion: metastatic OS.